EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) has reported E.P.S. of $-0.54 for its third fiscal quarter (ending September 30) versus $-0.33 for the same period a year ago — an increase of 64%. For the latest four quarters through September 30, E.P.S. were $-2.00 compared to $-2.66 a year ago — a decline of -25%.
Recent Price Action
EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) stock closed at $11.59 on 11/7/24 after a decline of -4.1%. NORMAL trading volume accompanied the decline. The stock has risen 1.1% during the last week but has been extremely weak relative to the market over the last nine months.
Current PriceTarget Research Rating
EYPT is expected to continue to be a modest Value Eraser reflecting capital returns that are forecasted to fall short of the cost of capital.
EyePoint Pharmaceuticals has a current Value Trend Rating of F (Lowest Rating). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing complementary signals. EyePoint Pharmaceuticals has a slightly negative Appreciation Score of 34 and a very low Power Rating of 0, resulting in the Lowest Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment